Repare Therapeutics has three most cancers drug candidates within the clinic and one other one anticipated to enter Part 1 by the tip of this 12 months. The biotech goals to make sure it has sufficient money to assist these packages, together with probably the most superior of them which lately misplaced its huge pharma associate, so it’s implementing a company restructuring that cuts out preclinical and discovery work.
The company shakeup will minimize about 25% of Repare’s workforce, principally these concerned in preclinical work, the corporate stated in its announcement after Wednesday’s market shut. Repare is headquartered in Montreal and in addition maintains operations in Cambridge, Massachusetts. Of Repare’s 179 whole staff as of February of this 12 months, 143 are concerned in R&D, in keeping with the corporate’s annual report.
Repare develops medicine that leverage an idea referred to as artificial lethality, through which a deficiency in a gene pair results in cell demise. A deficiency in a single gene is just not sufficient to kill a cell. Repare’s small molecule medicine goal the opposite gene in a pair to set off cell demise. Essentially the most superior Repare program is camonsertib, a drug designed to inhibit the DNA harm response protein ATR.
Two years in the past, Roche paid $125 million up entrance for world rights to camonsertib, which on the time had reached Part 1/2 testing in a variety of tumor varieties. Repare received’t be getting the as much as $1.2 billion in milestone funds specified by that deal. In February, Repare disclosed the pharma big had determined to terminate the alliance after “a overview of Roche’s pipeline and evolving exterior components.” A separate collaboration with Bristol Myers Squibb is ongoing. The Roche termination was efficient in Might. Camonsertib continues to be in Part 1/2 scientific testing. A research of the drug as a monotherapy for non-small cell lung most cancers is enrolling sufferers with ATR-inhibitor sensitizing mutations; preliminary knowledge are anticipated in 2025.
The Repare pipeline additionally contains lunresertib, which blocks a goal referred to as PKMYT1. A Part 1 take a look at of lunresertib together with camonsertib is underway on the really useful Part 2 dose in sufferers with ovarian and endometrial cancers. The corporate stated it expects to report knowledge from this research within the fourth quarter of this 12 months, which might set the stage for a registrational research in 2025.
In the meantime, RP-1664, an inhibitor of PLK4, is in Part 1 testing. The corporate expects to advance this drug to a Part 1/2 scientific trial enrolling pediatric sufferers with high-risk, recurrent neuroblastoma. RP-3647, Repare’s polymerase theta ATPase inhibitor, is on monitor to start a Part 1 dose-finding research within the fourth quarter of this 12 months.
In its report of second quarter 2024 monetary outcomes on Aug. 6, Repare stated its money place was $208.1 million, which it anticipated could be ample to fund operations into mid-2026. The board of administrators authorized the strategic reprioritization on Aug. 1, in keeping with an Aug. 28 Repare regulatory submitting. No point out of this company shake-up was made within the quarterly report. Repare expects to document a one-time money cost of $1.5 million to $2 million for termination advantages. The restructuring will save an estimated $15 million yearly, which extends Repare’s money runway into the second half of 2026, the corporate stated within the submitting.
“We acknowledge right this moment the extraordinary contributions and productiveness of our discovery staff, who’ve enabled the event of our deep, modern scientific portfolio,” Repare President and CEO Lloyd Segal stated in a ready assertion. “In our mission to quickly develop new, practice-changing therapies, we are going to extra absolutely dedicate our assets to our most promising and superior precision oncology packages to maximise worth for sufferers and for our shareholders.”
Illustration: Getty Pictures
